TrialNature medicine2022

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.

Jamie E Chaft et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.